Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B (N1VO34) Stock Price & Analysis

N1VO34 Stock Chart & Stats

$26.75$0.49(1.87%)

At close: Oct 30

Day’s Range: $26.59 - $27.22
52-Week Range: $22.90 - $42.43
Previous Close: $26.26
Volume: N/A
Average Volume (3M): 33.11K
Market Cap: BRL 958.14B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.30
Next Earnings: Nov 04, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B News

Cboe data suggests bullish flow in Novo Nordisk with shares up 1.49%

Cboe data suggests bullish flow in Novo Nordisk (NVO), with shares up 58c, or 1.49%, near $39.73. Options volume more than double the daily average with 49k contracts traded and

2d agoNVO NOV

AbbVie Science Chief says interested in building out obesity assets

AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that

2d agoLLY NVO

Moderately bullish activity in Novo Nordisk with shares up 1.27%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 48c, or 1.27%, near $38.77. Options volume roughly in line with average with 18k contracts traded and calls leading puts

3d agoNVO NOV

Moderately bullish activity in Novo Nordisk with shares up 0.24%

Moderately bullish activity in Novo Nordisk (NVO), with shares up 10c, or 0.24%, near $39.15. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call

5d agoNVO NOV

FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older

The U.S. Food and Drug Administration has approved Awiqli injection, a long-acting insulin analog, as an adjunct to diet and exercise to improve glycemic control in pediatric patients aged 10

1w agoNVO NOV

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)

WSW, NY, October 21st, 2026, FinanceWire Recent acquisitions and licensing deals reveal what drugmakers want next: different biology, better dosing and treatments that can complement existing medicines. Palatin is developing

1w agoNVO PTN

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.76%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 30c near $38.53. Options volume roughly in line with average with 65k contracts traded and puts leading

1w agoNVO NOV

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.14%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares down 6c near $39.16. Options volume relatively light with 18k contracts traded and calls leading puts for a

2w agoNVO NOV

Chinese factories making components for GLP-1s have mold, bugs, Bloomberg says

Two Chinese factories making components for GLP-1 drugs in America were found to be in poor conditions, with U.S. inspectors noting black mold on equipment and “gross contamination” on the

2w agoLLY NVO

Moderately bullish activity in Novo Nordisk with shares up 2.9%

Moderately bullish activity in Novo Nordisk (NVO), with shares up $1.10, or 2.9%, near $39.23. Options volume running well above average with 22k contracts traded and calls leading puts for

2w agoNVO NOV

Evotec appoints Joanna Holbrook as chief scientific officer

Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of

2w agoEVO NVO

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

Novo Nordisk, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on the stock and has a

1M agoNVO NOV

Novo Nordisk Kept at Hold as Analyst Maintains $47 Price Target Amid Strategic Uncertainty

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk yesterday and set a price target of $47.00. Evan Seigerman has given his Hold rating due to a

1M agoNVO NOV

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

WSW, NY, August 31st, 2026, FinanceWire The drugs that rebuild bone are locked inside a channel most patients never reach. Entera (NASDAQ:ENTX) is nearing the pivotal trial built to change

2M agoLLY NVO

N1VO34 FAQ

What was Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s price range in the past 12 months?

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B lowest stock price was $22.90 and its highest was $42.43 in the past 12 months.

What is Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s market cap?

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s market cap is R$958.14B.

When is Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B pay dividends?

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B does not currently pay dividends.

What is Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s EPS estimate?

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B have?

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B has 3,390,128,000 shares outstanding.

Which hedge fund is a major shareholder of Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B?

Currently, no hedge funds are holding shares in BR:N1VO34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B (N1VO34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	10	5	7
Technical Analysis	2	5	3
Moving Averages	8	0	4

Technical Analysis >

Similar Stocks

Stocks similar to BR:N1VO34
Company	Price & Change	Follow
BR:A1ZN34AstraZeneca PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.1666 ADR
BR:ABTT34Abbott Laboratories Shs Unsponsored Brazilian Depository Receipts Repr 0.083333333 S
BR:AMGN34Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh
BR:MDTC34Medtronic plc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh
BR:MRCK34Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh

Compare BR:N1VO34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft